Seroepidemiology of enterovirus A71 infection in prospective cohort studies of children in southern China, 2013-2018.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
26 11 2022
26 11 2022
Historique:
received:
08
05
2022
accepted:
11
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Enterovirus A71 (EV-A71)-related hand, foot, and mouth disease (HFMD) imposes a substantial clinical burden in the Asia Pacific region. To inform policy on the introduction of the EV-A71 vaccine into the National Immunization Programme, we investigated the seroepidemiological characteristics of EV-A71 in two prospective cohorts of children in southern China conducted between 2013 and 2018. Our results show that maternal antibody titres declined rapidly in neonates, with over half becoming susceptible to EV-A71 at 1 month of age. Between 6 months and 2 years of age, over 80% of study participants were susceptible, while one third remained susceptible at 5 years old. The highest incidence of EV-A71 infections was observed in children aged 5-6 months. Our findings support EV-A71 vaccination before 6 months for birth cohorts in southern China, potentially with a one-time catch-up vaccination for children 6 months-5 years old. More regionally representative longitudinal seroepidemiological studies are needed to further validate these findings.
Identifiants
pubmed: 36435844
doi: 10.1038/s41467-022-34992-1
pii: 10.1038/s41467-022-34992-1
pmc: PMC9701185
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7280Subventions
Organisme : Wellcome Trust
ID : ISSF204826/Z/16/Z
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2015 May 26;10(5):e0127999
pubmed: 26011735
PLoS Med. 2016 Feb 16;13(2):e1001958
pubmed: 26882540
PLoS One. 2012;7(5):e37206
pubmed: 22662137
Pediatrics. 2002 Jun;109(6):e88
pubmed: 12042582
Lancet Infect Dis. 2021 Mar;21(3):418-426
pubmed: 33031750
Lancet. 2022 Apr 30;399(10336):1708-1717
pubmed: 35427481
Lancet Neurol. 2010 Nov;9(11):1097-105
pubmed: 20965438
Emerg Infect Dis. 2016 Jan;22(1):92-5
pubmed: 26690000
Lancet Infect Dis. 2014 Apr;14(4):308-318
pubmed: 24485991
PLoS Negl Trop Dis. 2012;6(2):e1476
pubmed: 22348156
Vaccine. 1997 Feb;15(3):317-20
pubmed: 9139492
PLoS One. 2016 Nov 29;11(11):e0167269
pubmed: 27898715
EBioMedicine. 2021 Jun;68:103398
pubmed: 34049245
Pediatr Infect Dis J. 2015 Dec;34(12):1399-406
pubmed: 26368058
Vaccine. 2018 Jun 7;36(24):3445-3452
pubmed: 29739716
Vaccine. 2011 Dec 6;29(52):9668-74
pubmed: 22015395
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Mar 6;53(3):252-257
pubmed: 30841662
Chin Med J (Engl). 2010 Jul;123(13):1679-84
pubmed: 20819628
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Lancet Infect Dis. 2020 Mar;20(3):350-361
pubmed: 31870905
Euro Surveill. 2017 Dec;22(50):
pubmed: 29258646
Virol J. 2010 Nov 04;7:300
pubmed: 21050463
Virol J. 2012 Oct 29;9:248
pubmed: 23102275
PLoS One. 2011;6(7):e21116
pubmed: 21765891
J Biomed Sci. 2019 Oct 18;26(1):75
pubmed: 31627753
Clin Infect Dis. 2015 Mar 1;60(5):797-803
pubmed: 25352588
PLoS One. 2018 Dec 13;13(12):e0203792
pubmed: 30543631
Emerg Microbes Infect. 2021 Dec;10(1):619-628
pubmed: 33682641
Clin Infect Dis. 2018 Nov 13;67(11):1729-1735
pubmed: 29688329
Expert Rev Vaccines. 2018 Sep;17(9):819-831
pubmed: 30095317
J Med Virol. 2000 Jun;61(2):228-34
pubmed: 10797379
J Infect. 2016 Nov;73(5):509-512
pubmed: 27546063
China CDC Wkly. 2020 Mar 14;2(11):167-171
pubmed: 34594617
Lancet Infect Dis. 2020 Feb;20(2):230-239
pubmed: 31859216
Lancet. 2013 Jun 8;381(9882):2024-32
pubmed: 23726161
BMC Infect Dis. 2011 Oct 11;11:270
pubmed: 21988931
N Engl J Med. 2014 Feb 27;370(9):829-37
pubmed: 24571755
Hum Vaccin Immunother. 2015;11(11):2723-33
pubmed: 25715318